What Laboratory Professionals Need to Know: The Laboratory’s Role in AMR

Written by: Xiana Fontno

One Result Is Part of a Much Bigger Picture

You've just entered a final antimicrobial susceptibility testing (AST) report into a laboratory information system after performing AST on a positive blood culture isolate from a 65-year-old patient with suspected sepsis. The patient is receiving empiric therapy; however, the physician is awaiting AST results to select a targeted regimen.  You identified the organism and, after following isolation and inoculation procedures, applied antimicrobial disks onto an agar surface. You incubated the inoculated plates overnight before measuring the zones of inhibition and interpreting them using CLSI M100 guidelines. 

One Result Is Part of a Much Bigger Picture

You've just entered a final antimicrobial susceptibility testing (AST) report into a laboratory information system after performing AST on a positive blood culture isolate from a 65-year-old patient with suspected sepsis. The patient is receiving empiric therapy; however, the physician is awaiting AST results to select a targeted regimen.  You identified the organism and, after following isolation and inoculation procedures, applied antimicrobial disks onto an agar surface. You incubated the inoculated plates overnight before measuring the zones of inhibition and interpreting them using CLSI M100 guidelines. 

Now in the hands of the attending physician, the doctor reads your report. The bacterium causing the patient's sepsis is Escherichia coli. Your report says it's resistant to ampicillin and ciprofloxacin but is susceptible to ceftriaxone and several other antimicrobial agents. From there, the physician creates the targeted treatment plan for the patient and continues to monitor their response.   

Like some scientific experiments in a laboratory, antimicrobial stewardship is a practice that creates a chain reaction. It begins with a specimen from a patient and ends at their bedside. When health professionals across fields partake in standardized AST, whether it’s fungal, mycobacterial, or bacterial, it supports a bigger picture: stopping the emergence of antimicrobial resistance (AMR). The World Health Organization (WHO) states that AMR is a top global health threat that contributes to millions of deaths each year.  

This year, the WHO's World AMR Awareness Week (WAAW) has adopted the theme “One Health, one action: Prevent AMR now.” It serves as a reminder that everyone must do their part to fight AMR and the global health threat it poses not only to humans, but to animals, plants, and the environment. Whether you’re a policymaker, farmer, or in this case a laboratory professional, it’s vital that all sectors work in tandem to ensure the proper diagnostic measures and medicines are implemented through standardized AST . Everyone has a role, and for the laboratory professional, that role starts by looking at what happens to one patient's result.

 

It Starts with the Patient



In our scenario above, the physician relied on information generated by the laboratory to make a fully informed antimicrobial decision for the patient’s suspected infection. These results are driven from specimens collected from patients.   Submission of appropriate specimens and reliable culturing must also be addressed in addition to generating accurate AST results. Clinical staff can learn recommended collection techniques in various CLSI documents such as CLSI M47| Principles and Procedures for Blood Cultures which is particularly relevant in microbiology laboratories. 

Whether it is a phlebotomist, nurse, or physician taking the specimen from the patient, laboratories often dictate the entire preexamination process through institutional policies, validation protocols, and strict specimen rejection criteria. Bedside caregivers need to operate under a regulatory framework established through CLIA, CAP, and/or recommended guidance like standards from CLSI.  
 

The laboratory leads this process in several ways: 
 

  • Establishing a Specimen Collection Manual. Different stakeholders in a clinical or hospital setting work with laboratory staff to create a facility’s official specimen collection manual. This ensures expectations are understood and met each time bedside staff collects a sample from a patient. From instructions regarding skin preparation for blood volumes and labeling, everyone involved in a patient’s care must follow these instructions. 
     

  • Selecting and Supplying Collection Medium. In some situations, laboratories may supply staff with a specific collection medium that is compatible with its monitoring instruments. This dictates that bedside staff can only use specific containers approved and supplied by the laboratory. 
     

  • Applying Strict Acceptance Criteria. Laboratories may have procedures in place to reject a specimen if it does not satisfy the required conditions. This could be rejecting or flagging a cracked vial, unlabeled bottles, expired media, or anything that could compromise the test’s accuracy based on guidance that regulatory and accreditation organizations used to set these criteria. 
     

  • Working with Antimicrobial Stewardship. The antimicrobial stewardship team, which includes laboratory personnel, guides the laboratory in developing protocols that define what AST results are appropriate to report to physicians to help them determine the best treatment for the patient. For example, a laboratory may suppress broad-spectrum “last-resort" antimicrobial agents from the report if the organism is susceptible to narrower, safer first-line antimicrobial agents.  

 

Behind every AST result, there are laboratories that help provide the information needed to guide patient care.

 

From Specimen to Susceptibility: Turning a Test into Information

By the time our patient’s blood culture turns positive, the laboratory has already done a lot of work: collecting a quality specimen, growing the organism, and identifying it as E. coli. AST is the next step. It doesn’t find the pathogen. It asks which antimicrobial agents can stop the pathogen the laboratory already has identified. 

To set up the test, a laboratory professional mixes a few colonies into a sterile liquid until it reaches a standard cloudiness that resembles what is called a 0.5 McFarland standard. This step matters because the number of bacteria can change the result. Too many bacteria can make a working drug look like it failed, and too few can make a drug look better than it really is. 

Next, the laboratory exposes the bacteria to a panel of antimicrobial agents. Two common approaches are disk diffusion, where small disks containing different drugs are placed on an agar plate spread with the bacteria, and broth dilution, where the bacteria are placed in a series of drug concentrations from weak to strong. Laboratories may use other methods too, such as automated systems, but following standardized steps keeps results comparable from one laboratory to the next. 

After incubating for a set time, usually overnight, the laboratory professional reads the results. With disk diffusion, they measure the clear “halo” around each disk where bacteria did not grow. With broth dilution, they find the minimum inhibitory concentration (MIC): the lowest concentration of a drug that stops visible growth. 

Then the laboratory compares those measurements with the criteria used to interpret results which are referred to as “breakpoints” in CLSI M100 and categorizes each drug as susceptible, intermediate, or resistant. Think of these as predictions rather than promises. Susceptible means the drug is likely to work at standard dosing. Intermediate means it may work in certain situations, such as at higher doses or in body sites where the drug concentrates. Resistant means the drug is unlikely to work. 

The laboratory reports these results to the care team, who combines them with the patient’s symptoms and history to choose a treatment. Notice that the laboratory didn’tsimply generate a number. Methods, breakpoints, quality control, and reporting practices all shaped how that result became useful information. For our patient, that report helps the physician select an antimicrobial agent that is likely to work instead of defaulting to a broad-spectrum one. 

Want to dig deeper?  

CLSI M02 describes disk diffusion testing, CLSI M07 covers MIC methods for aerobic bacteria, and CLSI M100 provides the breakpoints. Other CLSI documents cover anaerobes (CLSI M11), fungi (CLSI M27, M38, and M44), numbers of mycobacteria and Nocardia (CLSI M24), and veterinary testing (CLSI VET01).

 

At the Bedside: How the Laboratory Informs Antimicrobial Stewardship

Treatment after AST is performed looks different after a patient is admitted into the emergency room and then given specialized care with a medical team. Instead of administering powerful broad-spectrum antimicrobial agents to cover every threat, members of the health care team practice good antimicrobial stewardship to make sure the patient is getting the right antimicrobial agent, at the right dose, for the right amount of time.  
 
With strong antimicrobial stewardship, medical teams not only protect their patients from potentially dangerous side-effects, but they also help prevent microorganisms from evolving resistance. Patients receiving a powerful dose of a broad-spectrum antimicrobial agent could be at risk of developing secondary infections or kidney toxicity based on their profile. But with a coordinated effort to carry out proper AST and using guidance like CLSI M100, the physician can be better informed to switch to a targeted, safer antimicrobial agent. 

When a patient is presenting with a severe infection like sepsis, every second counts as does every clinical decision in the antimicrobial agent choice. It’s up to pharmacists, physicians, laboratory staff, and other stakeholders to uphold antimicrobial stewardship by designing and acting on AST reports that ensure a patient’s safety but also safeguard against AMR from developing due to over-treatment or improper use of antimicrobial agents.  
 
The laboratory doesn’t see the patient, but it sees the pathogen and digs deeper to find the antimicrobial agents that have the best chance of stopping the infection. They provide information that is vital to helping others use antimicrobial agents more effectively.  

 

Across the Hospital: One Result Becomes a Pattern

 

A result may be for one patient in a room in one hospital, but the picture is much bigger. When laboratories consistently generate reliable results across many patients, those results can collectively reveal something more. Hundreds of results over time don’t just reflect every individual patient’s story; they reveal patterns with antimicrobial susceptibility and resistance in hospitals, health systems, or communities. Imagine a meteorologist tracking weather trends in a specific area over time. One rainy day may tell people to grab their umbrellas, but a pattern helps determine the climate. 
 

In a clinical microbiology laboratory, AST results aren’t just discarded after a patient’s case is closed. The results are kept and combined into master charts that can show susceptibility trends for antimicrobial agents versus certain organisms. For example, a hospital reports 90% of E. coli infections might be stopped by antimicrobial agent A, while only 60% of those infections might be treatable with antimicrobial agent B. For some infections, that data may help a doctor select a narrower spectrum rather than a broad-spectrum antimicrobial agent.  CLSI M39 | Analysis and Presentation of Cumulative Antimicrobial Susceptibility Test Data describes specific details for developing such charts, known as antibiograms, that reflect antimicrobial susceptibility rates.   

Compilation of AST results with presentation of the percentages of specific organisms that remain susceptible to an antimicrobial agent can give medical teams an early warning about possible emerging resistance patterns within their communities, and they can get a head start before treatments begin to fail.  Following a standard protocol for generating the data, such as that described in CLSI M39 is essential to be able to monitor these trends to help support infection prevention and stewardship activities throughout a hospital and community, and can begin to meet a much bigger expectation.

 

Across the Community: From Local Patterns to AMR Surveillance

 

A health system makes an AST report that is often collected by public health professionals in their municipality or even at a state level. This helps policymakers and health departments understand where resistance is happening, how resistance patterns are changing, and where emerging threats may require attention. Laboratory data collected from hospitals, clinics, and other facilities can all contribute to a wider surveillance system that will continue to monitor these trends and improve public health responses to AMR. 
 
Surveillance cannot accept just any laboratory result. It depends on reliable laboratory data obtained using standardized approaches. Using data from properly performed AST makes surveillance programs run on more meaningful data that is comparable between health systems.

 

Across Species and Sectors: AMR Doesn't Stop at the Human Health Laboratory



The WHO’s surveillance report has stated that AMR is no longer a growing concern, but a full-blown global health threat, and it doesn’t stop at humans. This year’s campaign emphasizes that AMR affects and is influenced by human health, animal health, food systems, and the environment. AMR has expanded rapidly to multiple branches of our communities, and scientists are working hard to understand resistant organisms that don’t recognize sector boundaries. 
 
Human and animal health laboratories encounter different pieces of the AMR picture. Think of AMR as a huge, interlocking puzzle. Bacteria do not care about what host they’re living in, but human hospitals and veterinary clinics treat different species, so their corners of the puzzle are different. The One Health approach combines data from both laboratories to get a better look at the full picture. CLSI supports this through both human standards like CLSI M100 and veterinary standards like CLSI VET01.  
 
Collaboration is vital under the One Health lens. When clinical teams are using standardized methods and share their data, doctors, vets, and public health officials can finally see how resistance moves through an entire community whether it starts at a farm, in a pet, the environment, or the hospital bedside.

 

What Laboratory Professionals Need to Know

 

As a laboratory professional working with humans, animals, public health or another area where AST and AMR surveillance are vital, what should you take away from this? 

Your results reach beyond the bench. 

Reliable AST results help support decisions about individual patients and can also contribute to understanding resistance at a broader level. 

Consistency matters. 

Standardized methods, current breakpoints, and strong quality practices help make laboratory results reliable and useful. 

Staying current matters. 

AMR evolves. Laboratory practices and breakpoints must evolve alongside new evidence. 

Collaboration matters. 

Laboratories are one piece of an interconnected response involving clinicians, pharmacists, infection prevention professionals, public health organizations, veterinarians, researchers, and others. 

The laboratory has a meaningful role in AMR response. 

Laboratory professionals may encounter AMR one specimen at a time, but the information they generate can have implications far beyond a single test. 

One Result, One Action, Bigger Impact 

 

AMR is a global challenge, but much of what we know about it begins locally with the patient. A specimen is tested following protocols written by a laboratory with input from relevant stakeholders. The laboratory determines susceptibility using a standardized approach. The final results help a doctor make an informed decision to treat a patient’s infection. Those results become part of a bigger impact. They’re reported and put into a surveillance program run by a public health department or other organization, and the data are used to track trends and understand resistance. 
 
So a laboratory’s role in AST and preventing AMR may start on a smaller scale at one clinic or one hospital with a single patient. But it then becomes vital information for an entire population. However, antimicrobial stewardship among stakeholders is the key to continuing the fight against AMR and reaching for a healthier future.  Today’s clinical decisions help build tomorrow’s solutions. 
 
Upcoming CLSI Micro Documents 

Looking for the latest guidance to help enhance your AST?  Here are upcoming CLSI documents to add to your laboratory’s AST collection: 
 
January 2027 

CLSI M52 | Verification of Commercial Microbial Identification and Antimicrobial Susceptibility Testing Systems, 2nd Edition 
 
CLSI M68 | Validation of Commercial Antimicrobial Susceptibility Test (AST) Breakpoints, 1st Edition 

CLSI M100 | Performance Standards for Antimicrobial Susceptibility Testing, 37th Edition 
 
CLSI M100 | Performance Standards for Antimicrobial Susceptibility Testing 

Explore more AST resources.

 

Works Cited

 

Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Disk Susceptibility Tests, 14th ed. CLSI standard M02. Clinical and Laboratory Standards Institute; 2024. 
 
Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing, 36th ed. CLSI supplement M100. Clinical and Laboratory Standards Institute; 2026. 
 
World Health Organization (WHO). Antimicrobial resistance. Fact sheet. July 16, 2026. Accessed November 11, 2026. https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance 
 
Centers for Medicare & Medicaid Services. (2025). Standard: Specimen submission, handling, and referral (42 C.F.R. § 493.1242). U.S. Department of Health and Human Services. https://www.ecfr.gov/current/title-42/part-493/section-493.1242 

Clinical and Laboratory Standards Institute. (2022). Principles and procedures for blood cultures (2nd ed., CLSI guideline M47). 

Doern, G. V., Carroll, K. C., Diekema, D. J., Garey, K. W., Rupp, M. E., Weinstein, M. P., & Sexton, D. J. (2019). Practical guidance for clinical microbiology laboratories: A comprehensive update on the problem of blood culture contamination and a discussion of methods for addressing the problem. Clinical Microbiology Reviews, 33(1), Article e00009-19. Doi.org 

Clinical and Laboratory Standards Institute. (2026). Performance standards for antimicrobial susceptibility testing (36th ed., CLSI supplement M100). 

Centers for Disease Control and Prevention. (2020). Selective reporting of antimicrobial susceptibility testing results: A primer for antibiotic stewardship programs. U.S. Department of Health and Human Services. https://www.cdc.gov/antibiotic-use/media/pdfs/selective-reporting-508.pdf 

Prinzi, A. M., & Rohde, R. E. (or primary author of the JCM stewardship review—see note below) / Simner, P. J., & Humphries, R. M. (2025). Antimicrobial susceptibility testing and reporting strategies: A simple and valuable antimicrobial stewardship tool. Journal of Clinical Microbiology, 63(7), Article e01708-24. doi.org

Sign Up for our Newsletter

You'll receive the latest updates on new standards, guidelines, and educational resources, as well as expert insights to help enhance your laboratory's performance and compliance.